3D-QSAR and docking studies on pyrrolopyrimidine derivatives as LIM-kinase 2 inhibitors

Letters in Drug Design and Discovery

Volumn 8, Issue 3, 2011, Pages 229-240

  Sun, Jun Rong ^a   Lan, Ping ^a   Sun, Ping Hua ^a   Chen, Wei Min ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

CoMFA; CoMSIA; Docking; Glaucoma; LIMK2

Indexed keywords

LIM KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CORRELATION COEFFICIENT; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; IC 50; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 79952294803     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011794578178     Document Type: Article

References (29)

1. Quigley, H.A.; Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol., 2006, 90, 262-267.
2. Weinreb, R.N.; Khaw, P.T. Primary open-angle glaucoma. Lancet, 2004, 363, 1711-20.
3. Rao, V.P.; Epstien, D.L. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs, 2007, 21, 167-177.
4. Johnson, M. What controls aqueous humour outflow resistance? Exp. Eye Res., 2006, 82, 545-57. (Pubitemid 43122085)
5. Woodward, D.F; Gil, D.W. The inflow and outflow of antiglaucoma drugs. Trends Pharmacol. Sci., 2004, 25, 238-241.
6. Marquis, R.E; Whitson, J.T. Management of glaucoma: focus on pharmacological therapy. Drugs Aging, 2005, 22, 1-21. (Pubitemid 40188902)
7. Tanihara, H.; Inatani, M.; Honjo, M.; Tokushige, H.; Azuma, J.; Araie, M. Intraocular pressure- lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol., 2008, 126, 309-315. (Pubitemid 351398453)
8. Harrison, B.A.; Whitlock, N.A.; Voronkov, M.V.; Almstead, Z.Y.; Gu, K.J.; Mabon, R.; Gardyan, M.; Hamman, B.D.; Allen, J.; Gopinathan, S.; McKnight, B.; Crist, M.; Zhang, Y.L.; Liu, Y.; Courtney, L.F.; Key, B.; Zhou, J.L.; Patel, N.; Yates, P.W.; Liu, Q.Y.; Wilson, A.G.E.; Kimball, S.D.; Crosson, C.E.; Rice, D.S.; Rawlins, D.B. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J. Med. Chem., 2009, 52, 6515-6518.
9. Scott, R.W.; Olson, M.F. LIM kinases: function, regulation and association with human disease. J. Mol. Med., 2007, 85, 555-568. (Pubitemid 46870893)
10. Takahashi, H.; Funakoshi, H.; Nakamura, T. LIM kinase as a regulator of actin dynamics in spermatogenesis. Cytogenet. Genome. Res., 2003, 103, 290-298. (Pubitemid 38445992)
11. Bernard, O. Lim kinases, regulators of actin dynamics. Int. J. Biochem. Cell Biol., 2007, 39, 1071-1076. (Pubitemid 46819128)
12. Lindsey, J.D.; Weinreb, R.N. Elevated intraocular pressure and transgenic applications in the mouse. J. Glaucoma, 2005, 14, 318-320. (Pubitemid 41023021)
13. Whitlock, N.A.; Harrison, B.; Mixon, T.; Yu, X.Q.; Wilson, A; Gerhardt, B.; Eberhart, D.E.; Abuin, A.; Rice, D.S. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J. Ocul. Pharmacol. Ther., 2009, 25, 187-194.
14. Sybyl 8.1, Tripos Inc., St. Louis, US.
15. Clark, M.; Cramer, R.D.; Van Opdenbosch, N. Validation of the general purpose tripos 5.2 force field. J. Comput. Chem., 1989,10, 982-1012.
16. Song, Q.L.; Sun, P.H.; Chen, W.M. Exploring 3D-QSAR for ketolide derivatives as antibacterial agents using CoMFA and CoMSIA. Lett. Drug Des. Discov., 2010, 7, 149-159.
17. Politi, A.; Durdagi, S.; Moulevelis-Minakakais. P.; Kokotos, G.; Papadopoulos, M.G.; Mavromoustakos, T. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel rennin inhibitors against cardiovascular diseases. Eur. J. Med. Chem., 2009, 44, 3703-3711.
18. Cichero, E.; Cesarini, S.; Possa, F.; Spallarossa, A.; Mosti, L. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. Eur. J. Med. Chem., 2009, 44, 2059-2070.
19. Zhang, N.; Zhong, R.G. Docking and 3D-QSAR studies of 7- hydroxycoumarin derivatives as CK2 inhibitors. Eur. J. Med. Chem., 2010, 45, 292-297.
20. Ibrahim, D.A.; El-Metwally, A.M. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur. J. Med. Chem., 2010, 45, 1158-1166.
21. Hu, R.; Barbault, F.; Delamar, M.; Zhang, R.S. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 2009, 17, 2400-2409.
22. Lan, P.; Huang, Z.J.; Sun, J.R.; Chen, W.M. 3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors. Int. J. Mol. Sci., 2010, 11, 3357-3374.
23. Cichero, E.; Cesarini, S.; Mosti, L.; Fossa, P. CoMFA and CoMSIA analyses on 4-oxo-1, 4-dihydroquinoline and 4-oxo-1, 4-dihydro-1, 5-, -1, 6- and -1, 8-naphthyridine derivatives as selective CB2 receptor agonists. J. Mol. Model., 2010, 16, 677-691.
24. Murumkar, P.R.; Giridhar, R.; Yadav, M.R. 3D-Quantitative Structure-Activity Relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-a converting emzyme. Chem. Biol. Drug Des., 2008, 71, 363-373. (Pubitemid 351347790)
25. Golbraikh, A.; Tropsha, A. Beware of q2. J. Mol. Graph. Model., 2002, 20, 269-276.
26. Roy, P.P.; Roy, K. On some aspects of variable selection for partial least squares regression models. QSAR Comb. Sci., 2008, 27, 302-313.
27. Lu, P.; Wei, X.; Zhang, R.S. CoMFA and CoMSIA 3D-QSAR on quionolone carboxylic acid derivatives inhibitors of HIV-1 integrase. Eur. J. Med. Chem., 2010, 45, 3413-3419.
28. Basu, A.; Jasu, K.; Jayaprakash, V.; Mishra, N.; Ojha, P.; Bhattacharya, S. Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives. Eur. J. Med. Chem., 2009, 44, 2400-2407.
29. Roy, K.; Paul, S. Docking and 3D-QSAR studies of acetohydroxy acid synthase inhibitor sulfonylurea derivatives. J. Mol. Model., 2010, 16, 951-964.